AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01087567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive insulin
Description: A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.
Study NCT01414647 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 300 g of strawberry, raspberry and cloudberry
Description: 100 g of strawberry puree, 100 g of frozen raspberries and 100 g frozen cloudberries were concumed daily for 8 weeks. Bilberry consumption was restricted.
Study NCT01414647 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 400 g of bilberry
Description: Equivalent amount to 400 g of fresh bilberries were consumed as 40 g of dried bilberries and as 200 g of frozen bilberries. Restriction of use of strawberries, raspberries and cloudberries were set.
Study NCT01087567 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Routine Care
Description: Treatment in routine care will be based upon the 2009 ADA treatment recommendations.
Study NCT00588783 — intervention group
Intervention type: DEVICE
Intervention: I-beam design
Description: This group will utilize tibial components with an I-beam design for total knee replacement.
Study NCT00588783 — intervention group
Intervention type: DEVICE
Intervention: Cruciate design
Description: This group will utilize tibial components with cruciate designs for total knee replacement.
Study NCT00190541 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesorectal excision with lateral lymph node dissection
Description: Mesorectal excision with lateral lymph node dissection
Study NCT00190541 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mesorectal excision without lateral lymph node excision
Description: Mesorectal excision without lateral lymph node excision
Study NCT02660541 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Betafoam
Description: Comparison between 2 medical devices
Study NCT02660541 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Allevyn Silver Dressing
Description: Comparison between 2 medical devices
Study NCT02135991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Getting To Outcomes
Description: These sites will receive written materials, training, and on site technical assistance to use the Getting To Outcomes process to implement Project CHOICE at their sites.
Study NCT02135991 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Project CHOICE
Description: Sites will receive standard training for Project CHOICE.
Study NCT02135991 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Project CHOICE
Description: Sites will receive standard training for Project CHOICE.
Study NCT01609270 — intervention group
Intervention type: DEVICE
Intervention: CardioRoot graft
Description: prospective single arm multi-center study to evaluate CardioRoot grafts implanted in a thoracic position.
Study NCT00827840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: 3mg to 12mg of Paliperidone ER once a day
Study NCT00827840 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone
Description: 1 to 6 mg of risperidone once or twice a day
Study NCT02061358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 3 mg
Description: Oral solution, single dose
Study NCT02061358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 10 mg
Description: Oral solution, single dose
Study NCT02061358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 30 mg
Description: Oral solution, single dose
Study NCT02061358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 90 mg
Description: Oral solution, single dose
Study NCT02061358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 180 mg
Description: Oral solution, single dose
Study NCT02061358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 360 mg
Description: Oral solution, single dose
Study NCT02061358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 720 mg
Description: Oral solution, single dose
Study NCT02061358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UV-4B 1000 mg
Description: Oral solution, single dose
Study NCT02061358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral solution, single dose
Study NCT01329120 — intervention group
Intervention type: PROCEDURE
Intervention: Minimally invasive repair of pectus excavatum
Description: Minimally invasive surgical technique basically consisting of inserting one or more convex steel bars under the sternum through small bilateral incisions in the thoracic wall
Study NCT01414647 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control diet
Description: Control diet, ie. habitual diet with restriction of berry consumption was consumed for eight weeks
Study NCT01329120 — intervention group
Intervention type: PROCEDURE
Intervention: Open surgical repair of pectus carinatum
Description: Open surgical removal the affected cartilages bilaterally and the excess cartilage over the sternum
Study NCT00322868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: All subjects treated for 28 days with pioglitazone, 30 mg orally, once daily.
Study NCT03290469 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clinical whole genome sequencing (cWGS)
Description: Clinical Whole Genome Sequencing (cWGS) consists of the sequencing, analysis and interpretation of subjects samples and a return of the result to the ordering physician.
Study NCT04271488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasurgratinib
Description: Tasurgratinib oral tablet.
Study NCT04646447 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-serine
Description: L-Serine Arm L-serine is considered as GRAS (generally recognized as safe) by the FDA and has been approved as a normal food additive under CFR172.320.~All patients will receive the same L-serine dose treatment over 12 months. Arm: Experimental: L-Serine 250 mg / kg / day during the first two weeks. From week 3 to 52, 500 mg / kg / day. L-serine orally administered, divided into three doses a day.~The L-Serine will be manufactured, packaged, labeled and/or distributed by NUTRICIA or delegated contractors. It will be presented in a powdered form of 100 gr of the amino acid L-serine. For oral use.~Sufficient L-serine will be dispensed at home considering the dose according the weight of the patient.
Study NCT01332240 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ultrasonography
Description: in order to stage the mediastinum
Study NCT00121199 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT00121199 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT00121199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00121199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00121199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV
Study NCT00121199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given PO
Study NCT00121199 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01256476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pitavastatin
Description: pitavastatin 4 mg once daily (QD)
Study NCT01256476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pravastatin
Description: Pravastatin 40 mg once daily (QD)
Study NCT02875678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABX-1431
Description: Single-dose ABX-1431
Study NCT02875678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single-dose matching placebo
Study NCT00225420 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: docetaxel
Description: Docetaxel will be administered per the designated cohort starting at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight treatments.
Study NCT00225420 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: leuprolide acetate
Description: Leuprolide acetate will be administered at 22.5 mg IM and will be initiated 2 to 3 months prior to radiotherapy and chemotherapy with docetaxel.
Study NCT02013869 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow-I, a modern anaesthetic machine without a bag/below/gas reservoir for compression of insufflation gas
Description: Desflurane Dialed setting 18 % on the machine gas vaporized
Study NCT02013869 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Asys, a anaesthetic machine with a bag/bellow for compression of gas to be insufflated
Description: Desflurane dialed 18% on the machine gas vaporized
Study NCT00225420 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Description: The total dose will be 7800 cGy in 200 centigray (cGy) per fraction for a total of 39 treatments.
Study NCT03673098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted 3RP
Description: The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The adapted 3RP intervention consists of 10, 90-minute weekly group sessions. Content specific to older women living with HIV, including self-compassion exercises, was added to the intervention in the first phase of this study (open pilot).
Study NCT05568485 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation was applied to the group with rheumatism
Description: Telerehabilitation was applied to the group with rheumatism in 3 sessions a week for 24 weeks via a social texting program. The intervention sessions consisted of 10 minutes of dance therapy-authentic movement, 40 minutes of exercises, and 10 more minutes of dance therap
Study NCT00005594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISIS 2503
Description: Beginning dosage of ISIS 2503 is 6 mg/kg/day given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. This will be repeated for the first two weeks of every three-week treatment cycle.
Study NCT04333836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Removable Clear Aligners
Description: 1. Plaster dental models will be poured from the rubber base impression.~2. Digital dental models will be created through scanning of plaster dental models.~3. Planning of the aligners will be done on 3 shape clear aligner studio®.~4. Aligners will be fabricated on 3d printed models using vacuum formers.~5. Anchorage reinforcement for posterior segments by using buccal miniscrews.~6. Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~7. Patient will receive the following aligner after 2 weeks.~8. Follow up visits every 2 weeks until complete canine retraction.
Study NCT04333836 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Removable Clear Aligners
Description: 1. Plaster dental models will be poured from the rubber base impression.~2. Digital dental models will be created through scanning of plaster dental models.~3. Planning of the aligners will be done on 3 shape clear aligner studio®.~4. Aligners will be fabricated on 3d printed models using vacuum formers.~5. Anchorage reinforcement for posterior segments by using buccal miniscrews.~6. Patient will receive the first aligner and will be instructed to wear it full time (except during eating and brushing) for 2 weeks.~7. Patient will receive the following aligner after 2 weeks.~8. Follow up visits every 2 weeks until complete canine retraction.
Study NCT00987792 — intervention group
Intervention type: DRUG
Intervention: Moxifloxacin (Avelox, BAY12-8039)
Description: Hospitalized patients receiving Avelox according to local drug information
Study NCT01809210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: selumetinib
Description: 2 x 25mg capsules bd continuously in cohort 1 (with gemcitabine and cisplatin). If tolerated - next cohort 3 x 25mg capsules bd continuously. if higher doses are explored, required number of capsules will be provided. Option to administer on D2-19 of each 21 day cycle if required to assess tolerability of combinations with chemotherapy
Study NCT01809210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 1250 mg/m2 iv on Day 1 and 8 of each 21 day cycle. If combination not tolerated, option to give 1000 mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
Study NCT01809210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75 mg/m2 iv on Day 1 of each 21 day cycle. If combination not tolerated, option to give 50 mg/m2 iv on Day 1 or 25mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
Study NCT00731367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Ag Gelled
Description: AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
Study NCT00731367 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aquacel Ag Adherent
Description: AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
Study NCT01388257 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: All types of surgery procedures
Description: All types of surgery procedures used for anoperineal fistula repair. Surgery procedures include fistulotomy, biological glue, rectal advancement flap and plug.
Study NCT01388257 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Simple seton drain removal
Description: Patients are simply followed after seton drain removal.
Study NCT01809210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: If it is not possible to identify a tolerable combination of selumetinib, gemcitabine and cisplatin, cisplatin may be replaced with carboplatin (AUC5) iv on Day 1 of each 21 day cycle
Study NCT01809210 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: Gemcitabine may be replaced with pemetrexed 500 mg/m2 iv on Day 1 of each 21 day cycle.
Study NCT00315627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Islet transplantation
Description: Islet transplantation
Study NCT03081208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nolasiban 900mg
Description: Nolasiban dispersible tablets for single oral administration
Study NCT03081208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo dispersible tablets for single oral administration
Study NCT01970917 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Olixia pure eye drops
Study NCT01970917 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Placebo
Description: 0.9% physiological saline solution
Study NCT02212236 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological preparation
Description: Ninety-minute, group-based psychological preparation delivered prior to haematopoietic stem cell transplantation aiming at alleviating psychological distress during the procedure by enhancing perceptions of the procedure and fostering more helpful coping.
Study NCT03852745 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Cognitive Behavioral Therapy
Description: cognitive behavioral therapy; focus on learning skills including acceptance and commitment
Study NCT01842555 — intervention group
Intervention type: OTHER
Intervention: Registry
Description: Registry
Study NCT01596673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)
Description: Phase B:~Eligible subjects will be randomized to treatment sequence XY or YX whereby treatment X is 60 mL of a noncarbonated flavored beverage and treatment Y is hydrocodone bitartrate powder at a dose strength of 45-mg reconstituted in 60 mL of a noncarbonated flavored beverage.~Phase C:~Eligible subjects will be randomly assigned to 1 of 4 treatment arms:~Treatment A: intact placebo tablet, 60 mL noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.~Treatment B: intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45-mg in 60 mL of a noncarbonated flavored beverage and 1 crushed placebo tablet.~Treatment C: intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet Treatment D: intact placebo tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet.
Study NCT01596673 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will consist of 60 mL of a non-carbonated beverage without the addition of active treatment
Study NCT01915264 — intervention group
Intervention type: DRUG
Intervention: Acarbose/Metformin (Glucobay M, BAY81-9783)
Description: Acarbose (25/50mg) and Metformin (500mg) in fixed dose combination.
Study NCT02284971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDX1127
Study NCT02284971 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Study NCT04509739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music intervention
Description: At 9 months of age, families will start the 12 - session intervention in a controlled laboratory space. In the initial session, caregivers will be given a brief orientation to intervention, including introducing them to the musical toys they will be using during the sessions with their infants and the lab environment. They will also be trained techniques through which they can synchronize the infant's movements to the experimenter's movements, such as clapping hand, tapping feet.~The remaining sessions will be scheduled in groups of 2-3 infant/parent dyads. In each session, a music CD with 15 minutes of selected children's music will be played and a musically trained experimenter will facilitate the sessions to engage the infants and parents to move to musical beats, using different musical toys, such as infant drums and maracas. Parents will be instructed to not to repeat any of these activities outside of the lab setting for the period of the study.
Study NCT04099251 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study NCT04099251 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Specified dose on specified days
Study NCT01607840 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: delivery of transcranial direct current stimulation or sham for 20 to 60 minutes
Study NCT01607840 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: delivery of transcranial direct current stimulation or sham for 20 to 60 minutes
Study NCT04050371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate
Description: All study participants received daily observed therapy with FTC/TDF.
Study NCT01314612 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Insomnia and Nightmare Group
Description: Group based cognitive-behavioral therapy meeting weekly for 90 minutes over the course of 9 weeks. Utilizes stimulus control, sleep scheduling, and progressive muscle relaxation to address symptoms of insomnia. Imagery rehearsal and rescripting are used to address nightmare symptoms.
Study NCT02269826 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagisan® Moisturising Cream
Description: Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
Study NCT02269826 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gynomunal® vaginal gel
Description: Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).